JP2019512021A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512021A5 JP2019512021A5 JP2018563406A JP2018563406A JP2019512021A5 JP 2019512021 A5 JP2019512021 A5 JP 2019512021A5 JP 2018563406 A JP2018563406 A JP 2018563406A JP 2018563406 A JP2018563406 A JP 2018563406A JP 2019512021 A5 JP2019512021 A5 JP 2019512021A5
- Authority
- JP
- Japan
- Prior art keywords
- cdk4
- inhibitor
- medicament according
- subject
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 14
- 229940083347 Cyclin-dependent kinase 4 inhibitor Drugs 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 230000026731 phosphorylation Effects 0.000 claims 7
- 238000006366 phosphorylation reaction Methods 0.000 claims 7
- 238000000034 method Methods 0.000 claims 5
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000000578 Cyclin-Dependent Kinase Inhibitor p21 Human genes 0.000 claims 1
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 claims 1
- 208000002231 Muscle Neoplasms Diseases 0.000 claims 1
- 102000000395 SH3 domains Human genes 0.000 claims 1
- 108050008861 SH3 domains Proteins 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- NMFKDDRQSNVETB-UHFFFAOYSA-N k00024 Chemical compound C1=CC=C2C3=C(C(=O)NC4=O)C4=C4C5=CC=C(Br)C=C5NC4=C3NC2=C1 NMFKDDRQSNVETB-UHFFFAOYSA-N 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298584P | 2016-02-23 | 2016-02-23 | |
| US62/298,584 | 2016-02-23 | ||
| PCT/US2017/019184 WO2017147326A1 (en) | 2016-02-23 | 2017-02-23 | P27 tyrosine phosphorylation as a marker of cdk4 activity and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019512021A JP2019512021A (ja) | 2019-05-09 |
| JP2019512021A5 true JP2019512021A5 (https=) | 2020-04-09 |
Family
ID=59686562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563406A Pending JP2019512021A (ja) | 2016-02-23 | 2017-02-23 | Ｃｄｋ４活性のマーカーとしてのｐ２７チロシンリン酸化およびそれを使用するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20190369104A1 (https=) |
| EP (1) | EP3419619A4 (https=) |
| JP (1) | JP2019512021A (https=) |
| CN (1) | CN109069485A (https=) |
| AU (1) | AU2017222575B2 (https=) |
| CA (1) | CA3013226A1 (https=) |
| WO (1) | WO2017147326A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111521810B (zh) * | 2019-02-02 | 2024-06-21 | 中国科学院上海药物研究所 | 癌症患者根据脾酪氨酸激酶进行分层 |
| JP2021167301A (ja) * | 2020-04-08 | 2021-10-21 | ファイザー・インク | Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置 |
| CA3184955A1 (en) * | 2020-07-06 | 2022-01-13 | Dominique Bridon | Brk peptides and methods of use |
| CN115252603A (zh) * | 2022-07-08 | 2022-11-01 | 深圳市第二人民医院(深圳市转化医学研究院) | indisulam在制备治疗膀胱癌的药物中的应用 |
| CN119639903B (zh) * | 2025-01-17 | 2025-11-25 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 用于肝内胆管癌的生物标记物、药物及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1788083A4 (en) * | 2004-08-02 | 2008-08-13 | Banyu Pharma Co Ltd | METHOD FOR THE ADOPTION OF MEDICAMENT SENSITIVITY AGAINST THE INHIBITOR CDK4 |
| WO2010096574A1 (en) * | 2009-02-20 | 2010-08-26 | Lisanti Michael P | A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm |
| US9376465B2 (en) * | 2012-03-27 | 2016-06-28 | University Of South Carolina | Cyclin based inhibitors of CDK2 and CDK4 |
| WO2015175965A1 (en) * | 2014-05-15 | 2015-11-19 | The Research Foundation For Suny | Compositions targeting the interaction domain between p27kip1 and brk and methods of use thereof |
-
2017
- 2017-02-23 WO PCT/US2017/019184 patent/WO2017147326A1/en not_active Ceased
- 2017-02-23 EP EP17757231.0A patent/EP3419619A4/en not_active Withdrawn
- 2017-02-23 JP JP2018563406A patent/JP2019512021A/ja active Pending
- 2017-02-23 AU AU2017222575A patent/AU2017222575B2/en not_active Ceased
- 2017-02-23 CN CN201780012955.0A patent/CN109069485A/zh active Pending
- 2017-02-23 US US16/075,900 patent/US20190369104A1/en not_active Abandoned
- 2017-02-23 CA CA3013226A patent/CA3013226A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512021A5 (https=) | ||
| Liu et al. | AURKA induces EMT by regulating histone modification through Wnt/β-catenin and PI3K/Akt signaling pathway in gastric cancer | |
| Languino et al. | Exosome-mediated transfer from the tumor microenvironment increases TGFβ signaling in squamous cell carcinoma | |
| Shan et al. | β2-AR-HIF-1α: a novel regulatory axis for stress-induced pancreatic tumor growth and angiogenesis | |
| Knapp et al. | Recently targeted kinases and their inhibitors—the path to clinical trials | |
| EP4335931A3 (en) | Therapeutic and diagnostic methods for cancer | |
| Beyens et al. | Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors | |
| Fujita et al. | Nitric oxide increases the invasion of pancreatic cancer cells via activation of the PI3K–AKT and RhoA pathways after carbon ion irradiation | |
| Moon et al. | p21-activated kinase 4 (PAK4) as a predictive marker of gemcitabine sensitivity in pancreatic cancer cell lines | |
| JP2017534583A5 (https=) | ||
| Zhang et al. | HPCAL 1 promotes glioblastoma proliferation via activation of Wnt/β‐catenin signalling pathway | |
| Qin et al. | Prognostic significance of RelB overexpression in non‐small cell lung cancer patients | |
| Yoo et al. | Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors | |
| Yeung et al. | K‐Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines | |
| Dacic et al. | RET rearrangements in lung adenocarcinoma and radiation | |
| Kornakiewicz et al. | Mammalian target of rapamycin inhibitors resistance mechanisms in clear cell renal cell carcinoma | |
| Schwab et al. | Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo | |
| Lai et al. | DEPTOR expression negatively correlates with mTORC1 activity and tumor progression in colorectal cancer | |
| Milhem et al. | Correlation of MTDH/AEG-1 and HOTAIR expression with metastasis and response to treatment in sarcoma patients | |
| Naderi | Molecular functions of brain expressed X-linked 2 (BEX2) in malignancies | |
| Haapasalo et al. | NRF2, DJ1 and SNRX1 and their prognostic impact in astrocytic gliomas | |
| Van Hook et al. | ΔN-ASPP2, a novel isoform of the ASPP2 tumor suppressor, promotes cellular survival | |
| Bozzi et al. | Evidence for activation of KIT, PDGFRα, and PDGFRβ receptors in the Ewing sarcoma family of tumors | |
| Adachi et al. | Rho-kinase inhibitor upregulates migration by altering focal adhesion formation via the Akt pathway in colon cancer cells | |
| Hanly et al. | Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells |